Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.

Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA

Open source

DOI
10.1136/jitc-2021-002939
Published
2021 Oct
Container
Journal for immunotherapy of cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2021-002939,
  title = {Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.},
  author = {Ghonime MG and Saini U and Kelly MC and Roth JC and Wang PY and Chen CY and Miller K and Hernandez-Aguirre I and Kim Y and Mo X and Stanek JR and Cripe T and Mardis E and Cassady KA},
  year = {2021},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2021-002939},
  url = {https://doi.org/10.1136/jitc-2021-002939}
}

RIS

TY  - JOUR
TI  - Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.
AU  - Ghonime MG
AU  - Saini U
AU  - Kelly MC
AU  - Roth JC
AU  - Wang PY
AU  - Chen CY
AU  - Miller K
AU  - Hernandez-Aguirre I
AU  - Kim Y
AU  - Mo X
AU  - Stanek JR
AU  - Cripe T
AU  - Mardis E
AU  - Cassady KA
PY  - 2021
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2021-002939
UR  - https://doi.org/10.1136/jitc-2021-002939
ER  - 

APA

MG, G., U, S., MC, K., JC, R., PY, W., CY, C., K, M., I, H., Y, K., X, M., JR, S., T, C., E, M., & KA, C. (2021). Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2021-002939

Source records